Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis (Q33288889)

25 July 2017

title

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis (English)

1 reference

25 July 2017

0 references

1 reference

James M Brophy

2

0 references

author name string

Vania Costa

series ordinal

1

1 reference

25 July 2017

publication date

25 June 2007

1 reference

25 July 2017

1 reference

25 July 2017

volume

7

1 reference

25 July 2017

page(s)

5

1 reference

Creative Commons Attribution 2.0 Generic

25 July 2017

copyright license

start time

25 June 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Local treatment pattern versus trial-based data: a cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Clinical experience with drotrecogin alfa in treating gram-positive and -negative pathogens in patients with severe sepsis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Activated protein C: do more survive?

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Drotrecogin alfa (activated) treatment of older patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Drotrecogin Alfa (Activated) in Severe Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2253-7-5

Should health care money in South Africa be spent on drotrecogin alfa?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1929064

Determinants of mortality in patients with severe sepsis

31 October 2018

1 reference

12 December 2020

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

1 reference

12 December 2020

Drotrecogin alfa (activated) in South African private hospital ICUs

1 reference

12 December 2020

Prescribing indications based on successful clinical trials in sepsis: a difficult exercise

1 reference

12 December 2020

Drotrecogin alfa (activated)

1 reference

12 December 2020

Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death

1 reference

12 December 2020

Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis

1 reference

12 December 2020

Recombinant activated protein C: decisions for administration

1 reference

12 December 2020

Sepsis in the ICU: who needs progress?

1 reference

12 December 2020

Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated)

1 reference

12 December 2020

When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated)

1 reference

12 December 2020

Drotrecogin alfa: too early to give it early

1 reference

12 December 2020

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure

1 reference

12 December 2020

Activated protein C: beyond 28 days

1 reference

12 December 2020

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

12 December 2020

Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables

1 reference

12 December 2020

Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis

1 reference

12 December 2020

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2253-7-5

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference